PD-L1 Testing

PD-L1 is an immune-related biomarker that is expressed on tumour cells in various tumour types, including Non Small Cell Lung Cancer (NSCLC). Assessing PD-L1 expression in squamous and non-squamous NSCLC may contribute to a better understanding of a patient's tumour and KEYTRUDA is indicated for the treatment of patients with metastatic NSCLC whose tumours express PD-L1. PD-L1 expression helps identify patients that are most likely to benefit from KEYTRUDA
Clinical details: 
The Dako PD-L1 22C3 pharmDx™ kit is a qualitative assay intended for use in the detection of PD-L1 in formalin-fixed, paraffin-embedded (FFPE) in non−small-cell lung carcinoma (NSCLC) using the Dako Autostainer Link 48 platform
Synonyms or keywords: 
Programmed Death Ligand 1
Sample type and Volume required: 
Sample Type: Formalin-fixed, paraffin-embedded (FFPE) slides
Volume: Fresh H&E slide and 3 unstained slides
Turnaround time: 
5 working days
Special sample instructions: 

Collection: unstained slides on positive-charged slides sectioned at 3 microns, sectioned of no more than one month age

Storage and transport: 
Refrigerate and protect from light and submit within 4 weeks of sectioning
Cellular Pathology at Guy's And St Thomas' Hospital
Histology: 0207 188 7188 extension 54611 , Cytology: 0207 188 2915, Oral Pathology: 0207 188 4367
Histopathology & Cytopathology Laboratories
Cellular Pathology
St Thomas' Hospital
North Wing - 2nd Floor
Westminster Bridge Road
London SE1 7EH

Head and Neck/Oral Pathology Laboratory
4th Floor, Tower Wing
Guy's Hospital
Great Maze Pond
London SE1 9RT

For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 30/06/2016